Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with revenue projections soaring to $4.3B by 2030. Read more here.
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval ...
El País in English19h
Kerstin Noëlle Vokinger: ‘New cancer therapies are being approved for patient groups not included in clinical trials’
Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...
The Lancet23h
Safe and equitable use of clinical decision support systems
TJH is on the MCBS working group for the European Society for Medical Oncology. Q-DT reports grants from Pfizer and consulting fees from Astellas, Bayer, Intuitive Surgical, Janssen, Novartis, and ...